Glucose Tolerance in Acromegaly: The Influence of GH-Excess on Glucose Metabolism and Insulin Resistance - Full Text View

Sponsors and Collaborators:	University Hospital Tuebingen Pfizer Ludwig-Maximilians - University of Munich
Information provided by:	University Hospital Tuebingen
ClinicalTrials.gov Identifier:	NCT00663000

Sponsors and Collaborators:

University Hospital Tuebingen
Pfizer
Ludwig-Maximilians - University of Munich

Information provided by:

University Hospital Tuebingen

ClinicalTrials.gov Identifier:

NCT00663000

Purpose

Observational, Cross-sectional, longitudinal, multi-center, diagnostic study

Cross-sectional part of the study: To evaluate the influence of acromegaly on glucose tolerance

Longitudinal part of the study: To evaluate the changes of impaired glucose tolerance during standard treatment of acromegaly. Adult patients with established acromegaly

Cross-sectional part of the study: 150 patients

Longitudinal part of the study: 58 patients

Condition
Acromegaly Diabetes Insulin Resistance Impaired Glucose Tolerance

MedlinePlus related topics: Diabetes

Drug Information available for: Insulin Dextrose

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Cross-Sectional
Official Title:	Observational, Cross-Sectional, Longitudinal, Multi-Center, Diagnostic Study to Evaluate the Influence of Acromegaly on Glucose Tolerance and to Evaluate the Changes of Impaired Glucose Tolerance During Standard Treatment of Acromegaly.

Further study details as provided by University Hospital Tuebingen:

Primary Outcome Measures:

To evaluate a correlation between IGF-I and glucose tolerance in patients with acromegaly.To evaluate changes of impaired glucose tolerance by different treatment options for acromegaly. [ Time Frame: cross-sectional; 1 year longitudinal ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

evaluate a correlation between body weight/BMI, age, family history of diabetes,duration of acromegaly and current medical treatment for acromegaly and glucose tolerance / insulin resistance [ Time Frame: cross-sectional, 1 year longitudinal ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

serum

Estimated Enrollment:	150
Study Start Date:	April 2008
Estimated Study Completion Date:	September 2010
Estimated Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts
acromegalics Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD). Written informed consent

Detailed Description:

TRIAL DESIGN Observational, cross-sectional (patients with normal glucose tolerance). longitudinal (patients with impaired glucose tolerance), multi-center, diagnostic study. After checking the inclusion and exclusion criteria for the cross-sectional part of the study patients will be included for anamnesis according to Flow Chart Visit -1 (Screening Visit). After checking the glucose tolerance and the insulin resistance by HOMA-IR, the patients will be classified to the group with normal glucose tolerance defined as:

fasting plasma glucose < 110 mg/dl and/or 2-hour plasma glucose after an OGTT < 140 mg/dl or to the group with impaired glucose tolerance defined as:
- fasting plasma glucose ≥ 110 mg/dl (IFG) and/or 2-hour plasma glucose after an OGTT ≥ 140 mg/dl (IGT). For the HOMA-IR the cut off is 1.5.

For patients with normal glucose tolerance the study will end after Screening Visit (V -1).

After patient recruitment of the cross-sectional part is completed an interim analysis is planned to verify that all criteria for the longitudinal study part are achieved. The longitudinal part should start not later than one year after the last patient was examined in the cross-sectional part. For patients with impaired glucose tolerance the inclusion and exclusion criteria for the longitudinal part of the study will be checked (Baseline, Visit 0).

If a patient might be included into the longitudinal part of the study a 12 months observation with 4 further visits will follow.

Primary Objective and Endpoint

Cross-sectional part of the study:

To evaluate a correlation between IGF-I and glucose tolerance in acromegalic patients. The inclusion should be performed in 2 stratification groups.

Following two groups are defined:

1/3 of patients with a controlled IGF-I (controlled means IGF-I in age and sex-related normal reference range.
2/3 of patients with an uncontrolled IGF-I (uncontrolled means IGF-I not in age and sex related normal reference range.

Longitudinal part of the study:

To evaluate changes of impaired glucose tolerance by different standard treatment options in acromegaly.

For the analysis of the different treatment options patients will be stratified into 5 treatment groups. Decision will be made according to next planned therapeutic intervention at Screening Visit (V -1):

Surgery
Treatment with somatostatin analoga (with or without combination of dopamine agonists)
Treatment with growth hormone receptor antagonist
Treatment with somatostatin analoga in combination with growth hormone receptor antagonist
Others (e.g. radiation, dopamine agonist monotherapy, no intervention)

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Acromegaly in adult subjects (≥ 18 years) either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).
Written informed consent

Criteria

Inclusion Criteria:

Acromegaly in adult subjects (≥ 18 years) either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value
- 2 SD).
Written informed consent

Exclusion Criteria:

Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or persistent ALT, AST, alkaline phosphatase 3 x > upper limit of normal, or total bilirubin 2 x > upper limit of normal.
Renal failure (GFR ≤ 30 ml/min)
Abnormal clinical laboratory values considered by the investigator to be clinically significant and which could affect the interpretation of the study results.
History of malignancy of any organ system, treated or untreated, within the past 3 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
Suspected or known drug or alcohol abuse.
Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion.
Participation in any other clinical trial with an investigational new drug.
Patients on longterm, continuous (more than 2 weeks/year) systemic therapy with glucocorticosteroids with exception of a substitution of a pituitary lack of ACTH/cortisol (e.g. patients with panhypopituitarism).
Instable heart insufficiency for example cardiomyopathy, congestive heart failure (NYHA class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation).
Type I diabetes according to the guidelines of the European Diabetes Society or obvious other manifestations of other forms of diabetes (e.g.

steroid diabetes).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00663000

Contacts

Contact: Baptist Gallwitz, MD, Prof.	49-707-1298-2093 ext 2093	baptist.gallwitz@med.uni-tuebingen.de
Contact: Karsten Muessig, MD	49-707-1298-0391 ext 0391	karsten.muessig@med.uni-tuebingen.de

Locations

Germany
Dept. Medicine IV	Recruiting
Tuebingen, Germany, 72076
Contact: Baptist Gallwiltz, MD, Prof. 49-707-1298-2093 ext 2093 baptist.gallwitz@med.uni-tuebingen.de
Contact: Karsten Muessig, MD 49-707-1298-0391 ext 0391 karsten.muessig@med.uni-tuebingen.de
Sub-Investigator: Karsten Muessig, MD
Internistische/Endokrinologische Praxis Dr. Droste	Recruiting
Oldenburg, Germany, 26122
Contact: Michael Droste, MD +49441219480 droste@endokrin-ol.de
Principal Investigator: Michael Droste, MD
Sub-Investigator: Inge Runge, MD
Dept. Internal Medicine, Div. Endocrinology, University of Magdeburg	Recruiting
Magdeburg, Germany, 39120
Contact: Kirsten Reschke, MD +493916713109 kirsten.keschke@medizin.uni-magdeburg.de
Principal Investigator: Kirsten Reschke, MD
Dept. Internal Medicine, Endocrinology, Max Planck Institute for Neuroscience and Psychiatry	Recruiting
München, Germany, 80804
Contact: Günther K Stalla, MD, Prof. +498930622270 stalla@mpipsykl.mpg.de
Principal Investigator: Günther K Stalla, MD, Prof.
Endokrinologikum Dresden	Recruiting
Dresden, Germany, 01069
Contact: Birgit Gerbert, MD +49351795670 birgit.gerbert@endokrinologikum.com
Principal Investigator: Birgit Gerbert, MD
Dept. Internal Medicine, Div. Endocrinology, Charité Campus Mitte, University of Berlin	Recruiting
Berlin, Germany, 10117
Contact: Christian Strasburger, MD, Prof. +4930450514152 christian.strasburger@charite.de
Principal Investigator: Christian Strasburger, MD, Prof.

Sponsors and Collaborators

University Hospital Tuebingen

Pfizer

Ludwig-Maximilians - University of Munich

Investigators

Principal Investigator:

Baptist Gallwitz, MD, Prof.

Dept. Medicine IV. Tuebingen University

Responsible Party:	Dept. Medicine IV ( Prof. Dr. Baptist Gallwitz / Principal Investigator )
Study ID Numbers:	T-7538, T-7538
Study First Received:	April 17, 2008
Last Updated:	March 2, 2009
ClinicalTrials.gov Identifier:	NCT00663000 History of Changes
Health Authority:	Germany: Ethics Commission; Germany: Federal Institute for Drugs and Medical Devices